MX2017014192A - Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. - Google Patents
Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.Info
- Publication number
- MX2017014192A MX2017014192A MX2017014192A MX2017014192A MX2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative disease
- compositions
- treating
- methods
- phenylsulfonyl
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se refiere a nuevos usos de antagonistas del receptor 5-HT6, específicamente 3- fenilsulfoni1-8-piperazinil -lil-guinolina o sales farmacéuticamente aceptables, hidratos, solvatos, o polimorfos, de la misma, y a la combinación de antagonistas del receptor 5-HT6, específicamente 3-fenilsulfoni1-8-piperazinil-lil-guinolina o sales farmacéuticamente aceptables, hidratos, solvatos, o polimorfos, de la misma, con otros agentes terapéuticos para el tratamiento de una enfermedad neurodegenerativa.
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158422P | 2015-05-07 | 2015-05-07 | |
US201562162193P | 2015-05-15 | 2015-05-15 | |
US201562162060P | 2015-05-15 | 2015-05-15 | |
US201562162068P | 2015-05-15 | 2015-05-15 | |
US201562162138P | 2015-05-15 | 2015-05-15 | |
US201562165034P | 2015-05-21 | 2015-05-21 | |
US201562168246P | 2015-05-29 | 2015-05-29 | |
US201562167986P | 2015-05-29 | 2015-05-29 | |
US201562169414P | 2015-06-01 | 2015-06-01 | |
US201562182225P | 2015-06-19 | 2015-06-19 | |
US201562189089P | 2015-07-06 | 2015-07-06 | |
US201562191189P | 2015-07-10 | 2015-07-10 | |
US201562201494P | 2015-08-05 | 2015-08-05 | |
US201562201513P | 2015-08-05 | 2015-08-05 | |
US201562239530P | 2015-10-09 | 2015-10-09 | |
US201562251534P | 2015-11-05 | 2015-11-05 | |
US201562256349P | 2015-11-17 | 2015-11-17 | |
US201562261115P | 2015-11-30 | 2015-11-30 | |
US201662289162P | 2016-01-29 | 2016-01-29 | |
US201662289643P | 2016-02-01 | 2016-02-01 | |
PCT/US2016/031367 WO2016179569A1 (en) | 2015-05-07 | 2016-05-06 | Compositions and methods of treating a neurodegenerative disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014192A true MX2017014192A (es) | 2018-08-01 |
Family
ID=57217933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014191A MX2017014191A (es) | 2015-05-07 | 2016-05-06 | Metodos de tratamiento de una enfermedad neurodegenerativa. |
MX2017014192A MX2017014192A (es) | 2015-05-07 | 2016-05-06 | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014191A MX2017014191A (es) | 2015-05-07 | 2016-05-06 | Metodos de tratamiento de una enfermedad neurodegenerativa. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160324852A1 (es) |
EP (2) | EP3291815A4 (es) |
JP (2) | JP2018515607A (es) |
KR (2) | KR20180021693A (es) |
CN (2) | CN107949386A (es) |
AU (2) | AU2016258198A1 (es) |
CA (2) | CA2985366A1 (es) |
HK (1) | HK1245078A1 (es) |
IL (2) | IL255421A0 (es) |
MX (2) | MX2017014191A (es) |
NO (2) | NO20171934A1 (es) |
WO (2) | WO2016179569A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY141862A (en) | 2003-07-22 | 2010-07-16 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
US20210346374A1 (en) * | 2016-10-03 | 2021-11-11 | Suven Life Sciences Limited | Pharmaceutical compositions of 5-ht6 receptor antagonist |
CA3043651A1 (en) * | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
WO2018102824A1 (en) * | 2016-12-02 | 2018-06-07 | Axovant Sciences Gmbh | Methods for treating neurodegenerative disease |
CN111032038A (zh) * | 2017-05-24 | 2020-04-17 | H.隆德贝克有限公司 | 用于治疗阿尔茨海默氏病的药物组合 |
MX2019013198A (es) | 2017-06-01 | 2020-01-20 | Eisai R&D Man Co Ltd | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). |
EP3628315A1 (en) * | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
PT3906927T (pt) * | 2020-05-04 | 2022-07-27 | Bioprojet Pharma | Utilização de agonistas parciais da dopamina d3 para o tratamento de distúrbios do sistema nervoso central |
EP4178961A1 (en) * | 2020-07-10 | 2023-05-17 | Agenebio, Inc. | Polymorphs of a gabaa alpha5 agonist and methods of using in the treatment of cognitive impairment |
CN112587534A (zh) * | 2020-12-23 | 2021-04-02 | 佑嘉(杭州)生物医药科技有限公司 | 阿伦酸在制备治疗肝纤维化药物中的用途 |
WO2023128900A1 (en) * | 2021-12-30 | 2023-07-06 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients |
WO2024040167A2 (en) * | 2022-08-18 | 2024-02-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Selective mc4r ligand for treating obesity and cognitive loss |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ535239A (en) * | 2002-03-27 | 2008-03-28 | Glaxo Group Ltd | Quinoline derivatives and their use as 5-HT6 ligands |
CA2604052C (en) * | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
WO2007147883A1 (en) * | 2006-06-23 | 2007-12-27 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
EP2254564A1 (en) * | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
CN104784173B (zh) * | 2008-10-28 | 2019-07-26 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
WO2011127235A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2016
- 2016-05-06 AU AU2016258198A patent/AU2016258198A1/en not_active Abandoned
- 2016-05-06 KR KR1020177035167A patent/KR20180021693A/ko unknown
- 2016-05-06 AU AU2016256923A patent/AU2016256923A1/en not_active Abandoned
- 2016-05-06 MX MX2017014191A patent/MX2017014191A/es unknown
- 2016-05-06 EP EP16790210.5A patent/EP3291815A4/en not_active Withdrawn
- 2016-05-06 JP JP2018510697A patent/JP2018515607A/ja active Pending
- 2016-05-06 CN CN201680036907.0A patent/CN107949386A/zh active Pending
- 2016-05-06 WO PCT/US2016/031367 patent/WO2016179569A1/en active Application Filing
- 2016-05-06 KR KR1020177035169A patent/KR20180022661A/ko unknown
- 2016-05-06 WO PCT/US2016/031359 patent/WO2016179566A1/en active Application Filing
- 2016-05-06 EP EP16790213.9A patent/EP3291816A4/en not_active Withdrawn
- 2016-05-06 US US15/149,053 patent/US20160324852A1/en not_active Abandoned
- 2016-05-06 CA CA2985366A patent/CA2985366A1/en not_active Abandoned
- 2016-05-06 CA CA2985370A patent/CA2985370A1/en not_active Abandoned
- 2016-05-06 JP JP2018510696A patent/JP2018519358A/ja active Pending
- 2016-05-06 CN CN201680036847.2A patent/CN107847499A/zh active Pending
- 2016-05-06 MX MX2017014192A patent/MX2017014192A/es unknown
-
2017
- 2017-11-05 IL IL255421A patent/IL255421A0/en unknown
- 2017-11-05 IL IL255423A patent/IL255423A0/en unknown
- 2017-12-05 NO NO20171934A patent/NO20171934A1/en not_active Application Discontinuation
- 2017-12-05 NO NO20171941A patent/NO20171941A1/en not_active Application Discontinuation
-
2018
- 2018-03-28 HK HK18104298.1A patent/HK1245078A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2985370A1 (en) | 2016-11-10 |
KR20180021693A (ko) | 2018-03-05 |
AU2016256923A1 (en) | 2017-11-23 |
JP2018515607A (ja) | 2018-06-14 |
JP2018519358A (ja) | 2018-07-19 |
US20160324852A1 (en) | 2016-11-10 |
AU2016258198A1 (en) | 2017-11-23 |
EP3291816A1 (en) | 2018-03-14 |
MX2017014191A (es) | 2018-08-01 |
IL255421A0 (en) | 2017-12-31 |
CN107847499A (zh) | 2018-03-27 |
KR20180022661A (ko) | 2018-03-06 |
EP3291816A4 (en) | 2019-01-02 |
EP3291815A1 (en) | 2018-03-14 |
IL255423A0 (en) | 2017-12-31 |
NO20171934A1 (en) | 2017-12-05 |
CN107949386A (zh) | 2018-04-20 |
CA2985366A1 (en) | 2016-11-10 |
WO2016179569A1 (en) | 2016-11-10 |
HK1245078A1 (zh) | 2018-08-24 |
EP3291815A4 (en) | 2019-01-16 |
WO2016179566A1 (en) | 2016-11-10 |
NO20171941A1 (en) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
MX2018006223A (es) | Moduladores de ror-gamma. | |
TW201613872A (en) | IRAK4 inhibiting agents | |
SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
NZ737399A (en) | Ccr2 modulators | |
MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
MX2018004664A (es) | Antagonistas de ep4. | |
PH12016502353A1 (en) | Pharmaceutical composition | |
PH12016502352A1 (en) | Pharmaceutical composition | |
MX2017005484A (es) | Compuestos antagonistas del receptor de dopamina d3. | |
MX2020011668A (es) | Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. | |
MX2017013877A (es) | Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
PH12016501483B1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
PH12017501736A1 (en) | Indole derivatives | |
MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. |